Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
NCT04957758
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
113
Enrollment
INDUSTRY
Sponsor class
Conditions
Neurotrophic Keratopathy
Interventions
DRUG:
OC-01 (varenicline) nasal spray 1.2 mg/ml
DRUG:
Placebo (vehicle) nasal spray
Sponsor
Oyster Point Pharma, Inc.